Sciwind Biosciences to Present Phase III Data on Ecnoglutide Injection at the 61st Annual Meeting of the European Association for the Study of Diabetes (EASD)
Hangzhou, China & San Francisco, U.S. – Sep 11, 2025 – Sciwind Biosciences, a clinical-stage biotech company focusing on metabolic diseases, today announced that Phase III clinical trial results of ecnoglutide injection for the treatment of overweight or obesity will be presented in a Short Oral Discussion at the 61st Annual Meeting of the European Association for the Study of Diabetes (EASD). The meeting will be held in Vienna, Austria, on September 15th–19th, 2025 (Central European Time).
Presentation Details
Title: A Phase 3 Evaluation of cAMP-biased GLP-1 Analogue Ecnoglutide in Adults with Overweight or Obesity
Session Theme: SO 073 The GLP-1 Portfolio: Diverse Formulations for Expanding Clinical Applications
Abstract Number: 826
Presenter: Ms. Qing Zheng
Date & Time: September 16th, 2025, 12:00–13:00 CEST (Central European Summer Time)
Format: Short oral presentation and poster display
About the European Association for the Study of Diabetes (EASD)
Founded in 1965 and headquartered in Düsseldorf, Germany, EASD is dedicated to promoting and supporting diabetes research, rapidly disseminating academic knowledge, and fostering its clinical application. The EASD Annual Meeting is Europe’s largest and most prestigious diabetes congress, renowned for cutting-edge basic science, landmark clinical trials, and in-depth expert discussions.
About Ecnoglutide
Ecnoglutide injection, originally discovered and developed by Sciwind Biosciences, is the first global, long-acting cAMP-biased GLP-1 receptor agonist enhancing biological efficacy and sustainability. Ecnoglutide injection has successfully completed three Phase III clinical trials, supporting Marketing Authorization Applications in China for treatment of adults with type 2 diabetes, as well as adults with obesity or overweight. From Phase I through Phase III, ecnoglutide injection has consistently demonstrated a favorable safety profile and strong efficacy, underscoring its potential as a promising therapy for patients with metabolic diseases.
About Sciwind Biosciences
Sciwind Biosciences is a clinical-stage biotech company focusing on discovering and developing innovative therapies to treat metabolic diseases. Sciwind has established a robust pipeline anchored by the lead asset, ecnoglutide (XW003), currently in the NDA stage in China. It has developed multiple proprietary technology platforms, including biased agonist discovery platform, long-acting and oral peptide delivery platforms, and has identified a series of drug candidates based on these core technology platforms. Sciwind has built an extensive pipeline targeting GLP-1 and synergistic pathways, offering both injectable and oral treatment solutions to deliver sustainable and high-quality therapies for patients with metabolic diseases.
For more information, please visit www.sciwindbio.com.
Contacts
General Information: PR@sciwindbio.com
Business Development: BD@sciwindbio.com